WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Role of ICH in Harmonising Drug Regulation

Gangu Sreelatha*, Ramgondola Vijaya Laxmi, Orugala Amulya

Department of Pharmaceutical Analysis, CMR College of Pharmacy, Kandlakoya, Hyderabad, Telangana, India – 501401
sreelatha1801@gmail.com
DOI: https://doi.org/10.55248/gengpi.5.0324.0860

ABSTRACT

International council for harmonization of technical requirements for pharmaceuticals for human use (ICH) is a joint initiative founded to collaborate regulatory authorities with the authorities of industries for taking part in scientific and technical discussions of testing procedures that help in ensuring efficacy and safety of the medications. The major contribution in developing ICH guidelines was by the regulatory and industrial authorities of Europe, Japan and the United States. Many other countries also have now joined hands with them to harmonise drug regulation worldwide. ICH has made very remarkable progress since its initiation. Most of the guidelines were implemented and maintained since the first ten years and thus they hold a solid foot without drifting between regions using the guidelines, which evidently shows why ICH still stands intact. ICH provides guidelines for quality, safety, efficacy and multidisciplinary aspects. This article will review the history, need for harmonisation, initiation and establishment of ICH, objectives, process of harmonisation, associated organisations and the guidelines.

KEYWORDS: ICH, Guidelines, Quality, Safety, Efficacy, Multidisciplinary, Regulatory authority, Industry

INTRODUCTION

New drugs are developed within the laboratories by scientists including chemists, pharmacologists who identify the cellular and genetic factors associated with the disease and make target molecules that have therapeutic value. In the beginning thousands of compounds are discovered, from which 4 to 5 are safe to be tested on humans after the preclinical trials. After 5 to 7 years of continuous clinical trials, on an average, only one compound among them reaches the market [1] .

The pharmaceutical industry is one among the largest global businesses. It is associated with constant innovation in terms of development of new drugs, adhering to safety, quality and efficacy and resolving issues related to profits, patent rights and protection [1] .At present, it is considered as the most highly regulated industry worldwide [2]. Earlier, variation in technical requirements from country to country led to the necessity of duplicating many time-consuming and expensive test procedures to release new medicines. This resulted in shooting up of the cost of research. Therefore, a need to rationalize and harmonize drug regulation came into existence, in order to make safe and efficacious treatments delivered to patients in the minimum amount of time [1]. The regulatory authorities fill this position. The purpose of regulatory agencies is to ensure the efficacy, safety, and quality of drugs and medical equipment. They also harmonise the legal processes involved in drug development and monitor and ensure that laws are being followed. They also play a crucial role in ensuring and boosting the application of regulations in unregulated regions of the world for the protection of those who live there. [2].

This is an innovative project for the registration of pharmaceutical products intended for human use. To debate the scientific and technological facets of product registration, this brings together regulatory authorities from Europe, Japan, and the United States with specialists from the pharmaceutical business in those three countries. [3]

NEED FOR HARMONISATION

The insight for having independent evaluation for every new drug and drugs that already existing the market was developed after witnessing several medical tragedies such as thalidomide in the late 1950S and early 1960s [3]. Cautious testing procedures began and escalated during the 1960s and 1970s. Both time and cost required for drug development shooted up dramatically in the two decades [4]. This instigated economic risks in drug development and the rate of attrition were estimated to be as high as 1:5,000-10,000 [5]. The creation of regulatory bodies followed, with the intention of offering strategic, tactical, and operational guidance and support for operating within the law to hasten the development and distribution of secure and efficient healthcare goods to people all over the world [2]. The industry at the time was expanding internationally and looking for new markets, but because technical standards varied so greatly from nation to nation, it became necessary for the industry to duplicate numerous time-consuming and expensive test procedures in order to market new products internationally. Standardized procedures would facilitate communication with corporations at the

programme design stage because the majority of regulatory authorities had limited resources to work with sponsor companies. Hence, the International Conference on Harmonization (ICH) was founded in 1990 with the goal of standardising the drug registration and approval procedure globally.

INITIATION AND ESTABLISHMENT

European Union developed the idea of harmonising regulatory requirements in the 1980s. they looked forward to developing single market for pharmaceuticals. It was evident that the harmonisation was realistic after remarkable success of the EU [3]. Soon in the 1989, Europe, Japan and the United States discussed about the potentials of harmonization. [1]in April 1990, at the WHO conference of drug regulatory authorities (ICDRA) in Paris hosted by EFPIA, at Brussels [3]. The International Conference on Harmonization (ICH) was founded shortly after the experts from the three areas approached the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) to develop a collaborative regulatory industry initiative on global harmonisation. Industry and regulatory agencies no longer have to assemble and evaluate distinct submissions for each region thanks to ICH's harmonised submission standards and standardised submission format [7].

The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) underwent a number of changes in 2015 and changed its name. This action was taken as a result of a 25-year history of successfully delivering harmonised rules for international pharmaceutical development and regulation, as well as a longer history of recognising the need for harmonisation. This elevated it to a worldwide endeavour

ICH, thus, became a legal, non-profit entity in Switzerland [6]. On 23rdOctober 2015, ICH held its inaugural assembly establishing itself as a legal international association under Swiss law [7] [3].

OBJECTIVES OF ICH

The goal of this harmonisation is to use human, animal, and material resources more sparingly and to stop needless delays in the global development and accessibility of new medicines while upholding regulatory requirements for the protection of public health and safeguards on product quality, safety, and efficacy [2]. It establishes a setting that gives all significant pharmaceutical regulatory agencies and industry stakeholders the chance to participate more actively in the process of pharmaceutical harmonisation [10]. By promoting higher economies of scale and creating a level playing field for regulatory compliance, it attempted to standardise the standards, format, and content of regulatory documentation. This reduces the pressure on drug prices. [3]

By 2015, the ICH's goal was stated in its Articles of Incorporation as follows:

- To provide proposals towards greater harmonisation in the interpretation and execution of technical standards and procedures for pharmaceutical product registration and the maintenance of such registrations;
- Maintaining a venue for productive communication on scientific concerns between regulatory bodies and the pharmaceutical sector on the standardisation of technical criteria for pharmaceutical goods;
- To add value to the international protection of public health in the interest of patients; To monitor and update harmonised specifications resulting in greater mutual acceptance of the results of research and development data;
- To prevent diverging future requirements by harmonisation of chosen issues required as a result of therapeutic advancements and the development of new technologies for the manufacturing of pharmaceutical goods;
- To enable the adoption of new or improved technical research and development techniques that update or replace present ones;
- To promote the appropriate application and integration of common standards through the distribution of, transmission of information about, and integration of training on, harmonised guidelines and their usage; and to formulate policy for the ICH Medical Dictionary for Regulatory Activities Terminology (MedDRA) while assuring the technical and scientific maintenance, growth, and promotion of MedDRA as a standardised glossary that enables the exchange of information. [11]

ORGANISATIONS ASSOCIATED

The European Union, European Federation of Pharmaceutical Industries and Associations, Ministry of Health, Labour and Welfare, Japan, Japan Pharmaceuticals Manufacturer's Association, Food and Drug Administration, USA, Pharmaceutical Research and Manufacturers of America, Swissmedic, and Health Canada comprise the Steering Committee that controls ICH's actions. The World Health Organization is present as an observer, while the International Federation of Pharmaceutical Manufacturers and Associations is a non-voting member. [1]

ACTIVE MEMBERS:

Founding regulatory members include FDA (United States), EC (Europe), MHLW/PMDA (Japan). Founding industry members include JPMA, EFPIA, phRMA. Standing regulatory members include Health Canada (Canada), Swissmedic (Switzerland). Regulatory Members include MFDS (Republic of

Korea), ANVISA (Brazil), HSA (Singapore), TITCK (Turkey), NMPA (China), SFDA (Saudi Arabia), TFDA (Chinese Taipei). Industry members include Global Self-care Federation, BIO, IGBA.

OBSERVERS:

Standing observers include IFPMA, WHO. Legislative or Administrative Authorities include CECMED (Mexico), AEC(Azerbaijan), CDSCO (India), ANMAT (Argentina), CPED (Israel), INVIMA (Colombia), SAHPRA (South Africa), JFDA (Jordan), MHRA (UK), MMDA (Moldova), Roszdravnadzor (Russia), MOPH (Lebanon), National Center (Kazakhstan), NRA (Iran), SCDMTE (Armenia), TGA (Australia). Regional harmonisation initiatives (RHIs) include APEC, ASEAN. EAC, GHC, PANDRH, SADC. International Pharmaceutical Industry Organisation include APIC. International Organisation regulated or affected by ICH Guideline(s) include Bill & Melinda Gates Foundation,EDQM, CIOMS, IPEC, PIC/S, USP [8].

GUIDELINES

The creation of ICH guidelines is a step-by-step procedure. In the first stage, the EWG creates a "final harmonised copy." Stage two is to forward the document to the Steering Committee for signing, indicating acceptability for comment. Stage three is a six-month or longer procedure of meetings and discussions with regulatory agencies in the three regions. Stage three also includes the publishing of the stage two guideline for public discussion. As a consequence of the consultation, fourth stage develops the Experts Document, which is subsequently forwarded to the Steering Committee. Stage four is accomplished when the Steering Committee approves the guideline's adoption by the regulatory bodies of the main regions. The process is finished in the last stage (stage five), when the recommendations are incorporated into national or regional internal processes. [13]

QUALITY GUIDELINES

Q1A-Q1F stability

Q1A (R2) Stability Testing of New Drug Substances and Products

This guideline recommends stability testing techniques for climatic zones I and II, including temperature, humidity, and trial length. Additionally, the amended protocol considers the criteria for stability testing in climatic zones III and IV, in minimising the varied storage conditions for worldwide dossier submission [14].

Q1B Stability Testing: Photostability Testing of New Drug Substances and Products

This document provides guidelines on the fundamental testing technique necessary to assess the light sensitivity and stability of novel medications and goods [15] [16].

Q1C Stability Testing for New Dosage Forms

This expands the principal stability guideline for novel preparations from already authorised drugs and describes the conditions within which lower stability data can be approved [17].

Q1D Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products

This is aimed at addressing recommendations on the use of bracketing and matrixing to stability studies conducted in compliance with the concepts indicated in the primary stability guideline [18].

Q1E Evaluation of Stability Data

This explains how extrapolation of retest intervals of shelf life might occur. Beyond real-time data may be relevant. It also includes instances of statistical techniques to stability data analysis [19].

Q1F Stability Data Package for Registration Applications in Climatic Zones III And IV

This leaves the specification of storage conditions in climatic zones II and IV. to various regions and WHO [20]

Q2- Analytical Validation

Q2 (R1) Validation of Analytical Procedures: Text and Methodology

This gives the validating conditions necessary for a range of analysing techniques and also addresses the qualities that must be regarded during the validation of the analytical processes contained in submissions [21].

Q2(R2)/Q14EWG Analytical Procedure Development and Revision ofQ2 (R1 Analytical Validation)

Q3A- Q3E Impurities

Q3A (R2) Impurities in New Drug Substances

This guideline covers the chemical and hazard concerns of impurities, such as the inclusion of impurities in specifications, and establishes the reporting, identification, and qualification limits [22].

Q3B (R2) Impurities in New Drug Products

It supplements the information on contaminants in new medication substances and offers suggestions on contaminants in products containing new chemically produced medicinal compounds [23].

Q3C (R8) Guidelines for Residual Solvents

This suggests using less harmful solvents in the manufacturing of medicine and dosage forms, as well as establishing pharmaceutical thresholds for residual solvents (organic volatile contaminants) in pharmaceutical formulations [24].

Q3D (R1) Guideline for Elemental Impurities

This regulates elemental contaminants in new pharmaceutical drugs and prescribes permitted daily exposures (PDEs) for 24 elemental impurities (EIs) for pharmaceutical drugs taken via the oral, parenteral, and inhalational routes [25].

Q3E EWG Impurity: Assessment and Control of Extractables and Leachable for Pharmaceuticals and Biologics

It benefits both registrants and policymakers by focusing on therapeutic considerations and increasing openness in medicinal product criteria, including drug delivery device components [26].

Q4A-Q4B Pharmacopoeias

Q4A Pharmacopeial Harmonisation

Q4B Evaluation and Recommendation of Pharmacopeial Texts for Use in The ICH Regions.

This guideline specifies a method for the Q4B EWG to evaluate and endorse chosen pharmacopeial literature for recognition by regulatory bodies as interchangeable in the ICH areas. The ICH decided to provide topical clauses containing information regarding the rules and its application [27].

Q5A-Q5E Quality of Biotechnological Products

Q5A (R1) Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin.

This section identifies the examination and assessment of the viral safety of biotechnology goods produced from human and animal cell lines, as well as the details which ought to be part of the marketing application or registration package. The goal of this guideline is to offer a basic framework for virus screening, experiments for viral clearance evaluation, and a suggested strategy for the designing of viral tests and viral clearance research [28] [29].

Q5A (R2) EWG Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin [9].

Q5B Analysis of The Expression Construct in Cells Used for Production Of rDNA Derived Protein Products.

This section is designed to detail the kinds of data that are regarded to be useful in evaluating the structure of the expression construct used to make recombinant DNA derived proteins [31].

Q5C Quality of Biotechnological Products: Stability Testing of Biotechnological/ Biological Products

This publication addresses the specific features of the stability testing process required to cater for the unique properties of proteins and/or polypeptides derived products [32].

Q5D Derivation and Characterisation of Cell Substrates Used for Production of Biotechnological/Biological Products

This document provides general guidelines on suitable standards for the synthesis of animal and human cell lines and cells derived from microbes, used to produce bioengineered products, as well as the production and assessment of cell banks for manufacturing [33].

Q5E Comparability of Biotechnological/ Biological Products Subject to Changes in Their Manufacturing Process

This paper outlines the guidelines for determining the comparability of biotechnological/ biological products before and after alterations to the production method of the pharmaceutical products. As a result, the purpose of this guideline is to aid in the collecting of important technical details that will provide proof that modifications to the manufacturing process will have no unfavourable effect on the quality, safety, and effectiveness of the medicine [34].

Q6A-Q6B Specifications

Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances

This guideline acts as a guide for the establishment and rationale of acceptance criteria, as well as the choosing of testing methods for new synthetic chemically derived pharmaceutical formulations and novel therapeutic products derived from them that haven't already been registered in the ICH areas [35].

Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products

This document establishes broad principles for the development and validation of a consistent collection of global standards for proteins and polypeptides derived from recombinant or non-recombinant cultured cells production methods [36].

Q7 Good Manufacturing Practice

Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients

This paper provides GMP recommendations for the manufacture of therapeutic ingredients in accordance with an adequate quality management system. It is also meant to assist in ensuring that APIs fulfil the quality and purity standards that they reflect onto the process [37].

Q8 Pharmaceutical Development

Q8 (R2) Pharmaceutical Development

This section guides on the topics of section 3.2.P.2 (pharmaceutical development) for pharmaceutical products, as described in the framework of module 3 of the common technical document [38].

Q9 Quality Risk Management

This guideline presents concepts and instances of quality risk management methods that may be used to many elements of biopharmaceutical quality. These facets usually involve the innovation, production, distribution, and evaluation and audit procedures for drugs and biotechnological products (which includes the utilization of raw resources, solvents, inactive ingredients, packaging, and labelling materials in drug (medicinal) products, biomedical, and biotechnological products) [39].

Q9 (R1) EWG Quality Risk Management

This focuses on the harmonising activities listed below:

- Implement only minor and targeted changes to particular sections and annexes of the present ICH Q9 guideline and quality risk management (QRM)
- Provide customised training resources (with cases) to strengthen the preexisting ICH briefing package on ICH Q9, and also to discuss and assist the suggested modifications' implementation and use [40].

Q10 Pharmaceutical Quality System

During the lifecycle of a product, this guideline is applicable to systems that assist the research and production of medications and biomedical products, including biotechnology and biological goods [41].

Q11 Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological or Biological Substances)

This guideline covers techniques to establishing and comprehending the drug substance production methods, as well as suggestions on what information should be supplied in module 3 of the common technical document (CTD) [42].

Q12 Life Cycle Management

Q12 Technical and Regulatory Considerations for Pharmaceutical Products Life Cycle Management

This new guideline is suggested to offer a structure to handle post-approval chemistry, manufacture, and controls (CMC) modifications in an easier, more foreseeable and equitable way throughout the lifecycle of a product.

Q12 IWG Training of Regulatory and Technical Considerations for Pharmaceutical Products Life Cycle Management

The Q12 IWG was formed to provide a detailed education program and relevant documentation to assist and harmonise the comprehension and execution of ICH Q12 in ICH and non-ICH locations [43].

Q13 Continuous Manufacturing of Drug Substances and Drug Products

This new guideline is recommended to:

• Incorporate essential legal and technical factors that support uniformity, including particular current good manufacturing practices (CGMP) aspects relevant to continuous manufacturing (CM)

• Enable drugs companies to use flexible techniques to design, execute, or incorporate CM for the synthesis of small molecules and therapeutic proteins for new and current pharmaceuticals (drug substances and drug products).

• Give regulatory expectations on the innovation, deployment, and evaluation of CM systems used in the manufacture of drugs and their products to the pharmaceutical industry and regulatory bodies [44].

Q14 Analytical Procedure Development

The new guidelines aim to harmonise scientific methodology to analytical procedure development and to give rules for describing the analytical procedure development process. It seeks to improve regulatory engagement among companies and regulators, in addition to attempting to promote more effective, proper empirical risk-based approvals and post-approval management of change of analysis tools [45].

SAFETY GUIDELINES

S1A-S1C Carcinogenicity Studies

S1A Need for Carcinogenicity Studies in Pharmaceuticals

This covers the scenarios under which carcinogenicity research on new medications are required. It contains identified risk factors, specified indications, and length of exposure [46].

S1B testing for carcinogenicity of Pharmaceuticals

This provides information on methods for assessing a pharmaceutical's carcinogenic risk [47].

S1C (R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals

This guideline assists in harmonising existing practises and improving research methodology by addressing the requirements to choose the highest dosage to be utilised in carcinogenicity studies on a novel medicinal drug [48].

S2 Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use

This guideline discusses in vitro and in vivo test protocols and assessment. It includes a dictionary of words related to genotoxicity testing to improve application dependability.

S2(R1) Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use

This guideline addresses two critical aspects of genotoxicity testing: the recognition of a series of standards tests which must be performed for registration and the extent of conclusive experimental research in any particular test in the standard battery [49].

S3A Note for Guidance on Toxicokinetic: The Assessment of Systemic Exposure in Toxicity Studies

This acts as a guide for obtaining toxicokinetic testing methods and highlights the importance of incorporating pharmacokinetics into toxicological analysis, assisting in the inference of study results, and promoting rational research methodology [50].

S3B Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies

This recommendation specifies the circumstances in which repetitive dosage tissue distribution experiments must be performed, such as when existing data resources are insufficient. It also makes advice on how such research should be carried out [51].

S4 Duration of Chronic Toxicity Testing in Animals (Rodent and Non-Rodent Toxicity Testing)

This act as a guide for the development of medical goods that are not previously provided by the ICH guideline on safety evaluations for biotechnological products including recombinant DNA proteins and monoclonal antibodies [52].

S5 (R3) Revision of S5 Guideline on Detection of Toxicity to Reproduction for Human Pharmaceuticals

This guideline incorporates expertise gained from assessing medications utilising existing and innovative research approaches, as well as recent breakthroughs in scientific, technical, and regulatory understanding. It also guarantees at least the same degree of human safety as current testing paradigms [53].

S6 (R1) Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals

This covers the standards for preclinical safety assessment for biotechnological products. It specifies how to employ animal models of illness, the timing of genotoxicity testing and carcinogenicity studies, and the effect of antibody production on the length of treatment.

S7A Safety Pharmacology Studies for Human Pharmaceuticals

It defines pharmacological and toxicological safety assessment, as well as basic concepts and suggestions. This policy applies to novel chemical substances and bioengineered goods for human use in general. It may be employed with marketed medications in suitable instances, for example when serious adverse events, a new patient group, or a novel dosage form create significant concerns [55].

S7B The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals

This paper describes a non-clinical assessment approach for determining a test substance's ability to delay ventricular repolarization. This recommendation includes information on non-clinical testing and integrated risk evaluations [56].

S8 immunotoxicity studies for human pharmaceuticals

This paper provides guidelines on nonclinical testing methodologies for identifying chemicals with immunotoxic potential, as well as information on a weight-of-evidence decision making strategy for immunotoxicity evaluation. It applies to both novel medications and existing drugs recommended for various conditions or other alterations on the present product label when the change may result in unresolved and significant immunotoxicity problems [57].

S9 non-clinical evaluation for anticancer pharmaceuticals

This guideline covers medications aimed at treating cancer in individuals having late-stage or severe illness, irrespective of how they are administered, and includes both small molecule and biotechnology-derived drugs. It defines the nature and timing of non-clinical investigations in the development of cytotoxic pharmaceuticals and refers to further recommendations as needed [58].

S10 Photo-safety evaluation of pharmaceuticals

This guideline establishes worldwide standards for photostability analysis and harmonises such evaluations in conjunction with human clinical studies and medical and health care approvals. [10].

S11 Non-clinical Safety testing in support of development of paediatric medicines

It specifies standards for the situations in which non-clinical juvenile animal experimentation is deemed useful and required to assist paediatric clinical studies, as well as guidelines for study design [60].

S12 EWG Non-clinical Biodistribution considerations for gene therapy products

The S12 EWG is developing a new S12 Guideline on Non-Clinical Biodistribution Factors for Gene Therapy Products, with the objective of offering guidance on the components of non-clinical research conducted that cover Biodistribution evaluation, and will make a contribution to the refined innovation of regenerative medicinal products while maintaining scientific credibility and reducing the superfluous usage of animals [61].

EFFICACY GUIDELINES

E1Clinical Safety for Drugs Used in Long Term Treatment

It guides on the patient population and period of exposure for evaluating the safety of medications designed for the long-term treatment of not-life-threatening illnesses [62].

E2A-E2FPharmacovigilance

E2AClinical Safety Data Management: Definitions and Standards for Expedited Reporting

Standardized definitions and terminology for important elements of clinical safety reporting are provided in this guideline. Furthermore, it provides instructions on how to handle accelerated (quick) reporting of adverse drug responses throughout the research stage of product development [63].

E2B(R3) Clinical Safety Data Management: Data Elements for Transmission of Individual Case Safety Report ICSR)

Implementation guide for ICH E2B (R3) Electronic transmission of individual case safety reports (ICSRs) - data components and message specification [64].

E2C(R2) Periodic Benefit-Risk Evaluation Report

When a medication has been launched, regulatory bodies must be periodically updated with safety data, which is outlined in this regulation. The goal of the directive is to prevent repetition of work and guarantee that the regulators get information on the overall safety expertise at predetermined intervals following commercialization [65].

E2D Post Approval Safety Data Management: Definition and Standards for Expedited Reporting

The guidelines for obtaining and reporting information is provided in this paper, together with a standard operating procedure for post-approval safety data management [66].

E2E Pharmacovigilance Planning

This recommendation is meant to help in the implementation of drug safety operations, particularly in advance of the early post-marketing phase of a novel drug (in this recommendation, the term drug denotes chemical entities, biotechnology-derived products, and vaccines) [67].

E2F Development Safety Update Report

The development Safety Update (DSUR) that is suggested in this policy is meant to serve as a uniform protocol for regular reporting on pharmaceuticals that are either in development or that have already been approved but are undergoing additional research throughout the ICH zones. [68]

E3 Clinical Study Reports

The structure and information of a clinical trial report acceptable to all regulatory agencies within the ICH territories are described in this document [69].

E4 Dose-Response Studies

Throughout the clinical development of a novel medicine, this document makes guidelines on the planning and execution of studies to evaluate the correlations between dosage, biodistribution in blood, and therapeutic effects [70]

E5(R1) Ethic Factors in The Acceptability of Foreign Clinical Data

This clarifies the idea of the bridging analysis that a new region may require to ascertain as to if statistics of another region are relevant to its cohort [71]. It also discusses the intrinsic factors of the drug recipient; cultural and environmental factors which might influence the outcomes of clinical research done in regions.

E6 Good Clinical Practice (GCP)

It outlines the obligations and demands placed on each everyone involved with the execution of clinical trials, including investigators, monitors, sponsors, and IRBs. GCP comprises addenda on the key documents as well as the investigator's brochure and addresses topics of surveillance, reporting, and recordkeeping of clinical studies.

E7 Clinical Trials in Geriatric Population

This paper offers suggestions on the unique attributes that should be taken into account when designing and carrying out clinical testing for drugs that are anticipated to be useful for the geriatric population.[72].

E8 General Considerations for Clinical Trials

The proposed revision would discuss a greater variety of trial designs and information sources, suggest the identification of a fundamental set of critical-to-quality factors adaptable to various trial forms, and offer a revised cross-referencing of all the other pertinent ICH guidelines that must be consulted while organising research studies [73].

E9 Statistical Principles for Clinical Trials

The statistical technique used in clinical testing for commercial applications submitted in the ICH areas is outlined in this. The guidelines provided here are particularly applicable to clinical studies that are carried out in the latter stages of development, which include a lot of efficacy confirmation trials [74].

E10 Choice of Control Groups in Clinical Trials

This article discusses the selection of control groups for therapeutic studies while taking into account their differing moral, interferential, and functional characteristics. It draws attention to the test sensitivity issue that impacts the efficacy of study protocol in many situations in active control equivalence/non-inferiority studies [75].

E11 (R1) Clinical Trials in Paediatric Population

Regulatory standards for paediatric research plans, frameworks for conducting sophisticated experiments in paediatric patient populations, and focused scientific and technical problems pertaining to these groups have progressed significantly over the past ten years without corresponding progress in unified guidance [76].

E12 Clinical Evaluation by Therapeutic Category

The therapeutic area guideline includes the clinical assessment of novel antihypertensive medications. It offers a set of guidelines for outcomes and study designs on which all ICH regions generally adhere.

E14 Clinical Evaluation Of QT

With respect to the planning, execution, assessment, and interpretation of clinical trials to evaluate a drug's capacity for delaying cardiac repolarization, this document offers advice to the sponsor [77].

E15 Definitions in pharmacogenetics/ pharmacogenomics

Key words in the fields of pharmacogenomics and pharmacogenetics, such as molecular diagnostics, pharmacogenomics, pharmacogenetics, and genetic information and specimen encoding classes, are defined within this guideline [78].

E16 Qualification of Genomic Biomarkers

In accordance with ICH E15 [79], the regulation makes advice for the background, organization, and structure of regulatory submissions for the qualifying of genetic biomarkers.

E17 Multi-Regional Clinical Trials

This recommendation offers advice on fundamental designs and planning concepts for multi-regional clinical trials (MRCT) [80].

E18 Genomic Sampling

In clinical trials, this article offers standardised guidelines for genetic information handling and sampling. By establishing a shared knowledge of crucial factors for the objective gathering, preservation, and best utilisation of genetic specimens and information, this approach will make it easier to conduct genetic research [81].

E19 Safety Data Collection

In certain late-stage pre-marketing or post-marketing trials, it may be suitable to utilise a focused approach to safety data gathering. This new guideline is suggested to establish standardised concepts so that when this could be beneficial and how this type of strategy might be carried out.

E20 Adaptive Clinical Trials

The E20 EWG is developing a new E20 Guideline on Adaptive Clinical Trials to serve as a straightforward and unified set of guidelines for the regulatory scrutiny of these research findings in a worldwide pharmaceutical research programme. This framework will address the layout, conduct, assessment, and inference of Flexible Drug Trials.

MULTIDISCIPLINARY GUIDELINES

M1 MedDRA – Medical dictionary for regulatory activities

This comprehensive and thoroughly harmonised medical language was created by the ICH to assist the international exchange of regulatory data for medicinal goods used among humans.

M2 electronic standards for the transfer of regulatory information

By evaluation and recommendations that were as transparent and generic as feasible, this was intended to facilitate global digital communications [82].

M3 non clinical safety studies

The unanimity which exists in relation to the kind, length, and scheduling of non-clinical safety research to back up the execution of clinical trials on humans and the commercial authorization of medicines is reflected in this recommendation [83].

M4 common technical document

The review and evaluation procedures have been revolutionised by the consensus to compile all quality, safety, and efficacy data in a single framework. This led to a standardised electronic submission, which in turn made it possible to establish good critique procedures.

M5 data elements and standards for drug dictionary

The consensus draught guideline includes listings of CVOs for dosage forms and units of measure, as well as ICH commercial criteria for pharmaceutical product IDs.

M6 gene therapy

This offers advice on the use of testing methods for the identification and description of shed viruses to industries and regulatory bodies, as well as guidelines on non-clinical and clinical investigations [84].

M7 Mutagenic impurities

This manual on structural activity relationships (SAR) assessment for genotoxicity aims to answer issues if combining contaminants with comparable warnings that could result in equivalent warnings that may have equivalent mechanisms of action is a good idea. [11] [12].

M8 electronic common technical document (eCTD)

The ICH M4 CTD Guidelines' usage in the setting of the eCTD raises a number of difficulties that the M8 EWG reviews technically and evaluates in regard to their effect. The M4 Annex: Granularity Document will be updated as a component of this project by the relevant M4 Working Group in line with the agreement, although M4 will keep possession of the granularity document [13].

M9 Biopharmaceutics classification system-based biowaivers

It covers biowaivers relying on the Biopharmaceutics Classification System (BCS). Although BCS-based biowaivers for BCS class I and class III medications may be appropriate, these two kinds of biowaivers are not universally recognised. As a result, drug companies must adopt various strategies depending on the location. The report makes suggestions in favour of the biopharmaceutics categorization of pharmaceuticals and the exemption from bioequivalence studies [88].

M10 Bioanalytical Method Validation

The suggestions in this policy addresses the technical regulatory standards for bioanalysis performed during the development of pharmaceuticals with both organic and chemical roots [88].

M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP)

It is suggested that this guideline organise treatment protocols thoroughly and uniformly, including both necessary and discretionary elements. A technical specification that utilises an accessible, non-proprietary criterion to allow electronic exchange of medical protocol data is one of two major sets of harmonised strategies that the guideline will outline. The other is a blueprint which allows detecting headers, common text, and a variety of data fields and terminologies which will serve as the foundation for efficiency in exchanging data.[89]

M12 Drug Interaction Studies

In order to provide a uniform procedure for designing, conducting, and analysing Pharmacological And toxicological Studies during the development of a Medicinal Product, the M12 EWG is focusing on the development of an entirely novel M12 guideline on pharmaceutical interactions [90].

M13 Bioequivalence for Immediate- Release Solid Oral Dosage Forms

It works on the emergence of the M13 guideline to harmonise bioequivalence study design and standards, that is envisioned to be advantageous to researchers and generic product developers because the same suitable methodology will be employed in numerous domains, minimising duplication of effort [91].

PROCESS OF HARMONISING

In accordance with the kind of ICH harmonisation effort, there are four different classes: formal ICH procedure, Q and A procedure, revision procedure, and maintenance procedure. The official ICH approach consists of 5 phases for developing new harmonised guidelines and putting them into action.

Step 1: Consensus building

In accordance with the objectives outlined in the Write - up, the WG creates a joint draught of the Technical Document. The WG's skilled professionals will sign the Step 1 Specialists sign-off document once the group has agreed on the draught. The Council would then be asked to accept the Step 1 Experts Technical Document under Step 2 of the ICH procedure.

Step 2a: Confirmation of consensus on the Technical Document

Step 2a is achieved once the Council decides that there is enough scientific agreement on the technical concerns, relying on the WG's report, for the Technical Memorandum to move on to the following regulatory consultation stage. The Step 2a Technical Document is then approved by the Council.

Step 2b: Endorsement of draft Guideline by Regulatory Members

When the Statutory Council members further approve the draught Guideline, step 2b is reached.

Step 3: Regulatory consultation and discussion

The Step 3 Specialist Draft Guideline is finalised after three separate stages: regulatory outreach, review, and discussion.

Stage I - Regional regulatory consultation*:* The scientifically consensus-based policy exits the ICH process and is expected to undergo extensive regulatory scrutiny in the ICH areas. Regulatory agencies and business organisations from other areas are also welcome to offer their feedback on the draught discussion materials by sending it to the ICH Secretariat.

- ***Stage II - Discussion of regional consultation comments:*** The EWG works to deal with the problems obtained and come to an agreement regarding the document called Step 3 Experts Draft Guideline after collecting all remarks from the discussion phase
- ***Stage III - Finalization of Step 3 Experts Draft Guideline:*** The Step 3 Expert Draft Guideline is certified by expertise of the ICH Regulatory Members if, following careful evaluation of the outcomes of the WG's discussion, the experts agree on a revised version of the Step 2b draught Guideline. To propose acceptance at Step 4 of the ICH procedure, the Step 3 Expert Draft Guideline is presented to the Regulatory Assembly Members in accordance with regulatory EWG signatures.

Step 4: Adoption of an ICH Harmonized Guideline

When the Regulatory Representatives of the Assembly concur that the draught guideline has enough support from the research community, the process moves to step 4 and they endorse the ICH Harmonized Guideline.

Step 5: Implementation

The regulatory implementation phase of the procedure is promptly followed by the ICH Harmonized Guideline. This process is executed in accordance with the exact national/regional guidelines that are used for other regional regulatory guidelines and norms in the ICH regions.

The ICH Secretariat updates the ICH website with data on the regulatory measures undertaken, the execution references, and sends it back to the council.

CONCLUSION

ICH is a regulatory body formed to collaborate between different countries in setting similar standards for manufacturing pharmaceutical products. It has succeeded in the process of harmonisation and has eased the cost of production and duplication of qualitative tests. ICH guidelines are followed in all the reputed pharmaceutical industries in India. Quality guidelines are followed in QC and QA departments, Safety guidelines in R&D department, Efficacy guidelines in the Clinical Trials and Multidisciplinary in the maintenance and transfer of all the data. ICH shall be implemented in the upcoming industries too, for smooth functioning of industry and for obtaining quality and safe products.

REFERENCES

[1] J. Singh, "International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use," Journal of Pharmacology and Pharmacotherapeutics, 2015.

[2] P. T. Geethanjali Sengar, "Pharmaceutical regulatory agencies and organisations around the world: scope and challenges in drug development," Pharmatutor, 2012.

[3] "History," [Online]. Available: https://www.ich.org/page/history.

[4] y. ohno, "ICH guidelines-Implementation of the 3Rs (Refinement, Reduction and Replacement): incorporating best scientific practices into the regulatory process," ILAR, 2002.

[5] J. A. DiMasi, "Trends in drug development costs, times and risks," Sage, 1995.

[6] Z. Brennan, "ICH makes organisational changes," 2015.

[7] "ICH is now international council for harmonisation- a legal swiss entity," 2015.

[8] "Members and Observers," [Online]. Available: https://www.ich.org/page/members-observers.

[9] "Final concept paper Q5A (R2): Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin".

[10] "S10 Photo safety evaluation of pharmaceuticals".

[11] Final Concept Paper ICH M7(R2)：Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk".

[12] ICH guideline M7 on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk".

[13] Final Concept Paper M8 : Electronic Common Technical Document".

[14] A. R. Shivali Rahi, "Role of ICH guidelines in registration of pharmaceutical products," IJDRA.

[15] A. G. L. L. JA Molzon, "The value and benefits of the international conference on harmonisation to drug regulatory authorities: Advancing harmonisation for better public health," 2011.

[16] ICH guideline implementation," [Online]. Available: https://www.ich.org/page/ich-guideline-implementation.

[17] "mission," [Online]. Available: https://www.ich.org/page/mission.

[18] D. J. Tao Wang, "ICH guidelines: inception, revision and implication for drug development," Toxicological sciences, 2010.

[19] F. W. Rockhold, "Industry perspectives on ICH guidelines," Statistics in Medicine, 2002.

[20] dwgyugdi, "jksxnkankj".

[21] "ICH topic Q1A (R2) stability testing of new drug substances and products".

[22] "ICH topic Q1C stability testing: requirements for new dosage forms".

[23] "ICH topic Q1D Bracketing and matrixing designs for stability testing of drug substances and drug products".

[24] ICH topic Q1E Evaluation of stability data".

[25] "Stability testing of active pharmaceutical ingredients and finished pharmaceutical products".

[26] "ICH Topic Q2 (R1) validation of analytic procedures: text and methodology".

[27] "ICH Q 3A (R2) impurities in new drug substances".

[28] "ICH Topic Q3B (R2) impurities in new drug products".

[29] "Final concept paper Q3C: impurities: guidelines for residual solvents dated and endorsed by the steering committee".

[30] “ICH guideline Q3D (R1) on elemental impurities”.

[31] “Final concept paper ICH Q3E: guideline for extractables and leachables (E & L),” 30 june 2020.

[32] “Evaluationa nd recommendadtion of pharmacopoeial text for use in the ICH regions Q4B”.

[33] “Viral safety evaluation of biotevhnology products derived from cell lines of human or animal orgin Q5A (R1)”.

[34] “ICH Topic Q5A (R1) Quality of biotechnological products: Viral safety evaluation of biotechnology products dervied from cell lines of human or animal origin”.

[35] “ICH topic Q5B Quality of biotechnological products: analysis of the expression construct in cell lines used for production of rDNA derived protein products”.

[36] “ICH Q5C stability testing of biotechnological/biological products”.

[37] “ICH Q5D derivation and characterisation of cell substrates used for peoduction of biotechnological/biological products”.

[38] “ICH Q5E biotechnological/ biological products subject to changes in their manufacturing process: comparability of biotechnological/biological products”.

[39] “ICH topic Q6A specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemica1 substances”.

[40] “ICH topic Q6B specifications: test procedures and acceptance criteria for biotechnological/biological products”.

[41] “ICH topic Q7 good manufacturing practice for active pharmaceutical ingredients”.

[42] “ICH guideline Q8 (R2) on pharmaceutical development”.

[43] “ICH guideline Q9 on Quality Risk Management”.

[44] “Final concept paper ICH Q9 (R1)-Quality Risk Managemnet endorsed by the management committee”.

[45] “ICH guideline Q10 on Pharmaceutical Quality System”.

[46] “ICH guideline Q11 on Development and manufacture of drug substances (chemical entities and biotechnological/biological entities)”.

[47] “Technical and regulatory considerations for pharmaceutical product lifecycle management Q12”.

[48] “Final concept paper ICH Q13: Continuous manufacturing of drug substances and drug products”.

[49] “Final concept paper ICH Q14: analytical procedure development and revision of Q2 (R1) analytical validation”.

[50] “ICH Topic S1A the need for carcinogenicity studies of pharmaceuticals”.

[51] “ICH Topic S1B Carcinogenicity: testing for carcinogenicity of pharmaceuticals”.

[52] “ICH topic S1C (R2) dose selection for carcinogenicity studies of pharmaceuticals”.

[53] “ICH guideline S2 (R1) on genotoxicity testing and data interpretation for pharmaceuticals intended for human use”.

[54] “ICH topic S3A toxicokinetics: a guideline for assessing systemic exposure in toxicology studies”.

[55] “ICH topic S3B pharmacokinetics: repeated dose tissue distribution studies”.

[56] “ICH topic S4 duration of chronic toxicity testing in animals (Rodent and non-rodent toxicity testing)”.

[57] “ICH S5 (R3) guideline on reprodutive toxicology: detection of toxicity to reproduction for human pharmaceuticals”.

[58] “ICH guideline S6 (R1) – preclinical safety evaluation of biotechnology-derived pharmaceuticals”.

[59] ICH S7A Safety pharmacology studies for human pharmaceuticals”.

[60] “ICH Topic S 7 B The nonclinical Evaluation of the Potential for delayed Ventricular Repolarization”.

[61] “ICH Topic S 8 Immunotoxicity Studies for Human Pharmaceuticals”.

[62] “ICH guideline S9 on nonclinical evaluation for anticancer pharmaceuticals”.

[63] “S 12 Animal testing”.

[64] “CPMP/ICH/375/95”.

[65] “ICH E2A Clinical safety data management: definitions and standards for expedited reporting”.

[66] “ICH E2C (R2) Periodic benefit-risk evaluation report”.

[67] “ICH E2D Post-approval safety data management”.

[68] “ICH Topic E 2 E Pharmacovigilance Planning (Pvp)”.

[69] “ICH guideline E2F on development safety update report”.

[70] “ICH E3 structure and content of clinical study reports”.

[71] “ICH E4 Dose response information to support drug registration”.

[72] “ICH Topic E 5 (R1) Ethnic Factors in the Acceptability of Foreign Clinical Data”.

[73] “ICH Topic E 7 Studies in Support of Special Populations: Geriatrics”.

[74] “ICH Topic E 9 Statistical Principles for Clinical Trials”.

[75] “ICH E11(R1) guideline on clinical investigation of medicinal products in the pediatric population”.

[76] “ICH E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs”.

[77] “ICH Topic E15 Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories”.

[78] “ICH E16 Genomic biomarkers related to drug response: context, structure and format of qualification submissions”.

[79] “ICH guideline E17 on general principles for planning and design of multi-regional clinical trials”.

[80] “ICH guideline E18 on genomic sampling and management of genomic data”.

[81] “Final Concept Paper M2: Electronic Standards for the Transfer of Regulatory Information”.

[82] “ICH M3 (R2) Non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals”.

[83] “Final Concept Paper M6: Guideline on Virus and Gene Therapy Vector Shedding and Transmission”.

[84] “ICH M9 guideline on biopharmaceutics classification system-based biowaivers”.

[85] “Final endorsed Concept Paper M10: Bioanalytical Method Validation”.

[86] “Final Concept Paper ICH M11: Clinical electronic Structured Harmonised Protocol (CeSHarP)”.

[87] “Final Concept Paper M12: Drug Interaction Studies”.

[88] “Final Concept Paper M13: Bioequivalence for Immediate-Release Solid Oral Dosage Forms”.

[89] “ICH Q1B Photostability testing”.

[90] “ICH Q1B Photostability testing- Final concept”.

[91] “s11-nonclinical-safety-testing-support-development-paediatric-medicines-step-2b-draft”.

[92] “E8 (R1) EWG”.

[93] “ICH topic E10 choice of control groups in clinical trials”.

[94] “E2B-r3-electronic-transmission-individual-case-safety-reports”.